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Cytisine, a natural product with high affinity for clinically relevant nicotinic
acetylcholine receptors (nAChRs), is used as a smoking-cessation agent. The
compound displays an excellent clinical profile and hence there is an interest in
derivatives that may be further improved or find use in the treatment of other
conditions. Here, the binding of a cytisine derivative modified by the addition
of a 3-(hydroxypropyl) moiety (ligand 4) to Aplysia californica acetylcholine-
binding protein (AcAChBP), a surrogate for nAChR orthosteric binding sites,
was investigated. Isothermal titration calorimetry revealed that the favorable
binding of cytisine and its derivative to AcAChBP is driven by the enthalpic
contribution, which dominates an unfavorable entropic component. Although
ligand 4 had a less unfavorable entropic contribution compared with cytisine, the
affinity for AcAChBP was significantly diminished owing to the magnitude of
the reduction in the enthalpic component. The high-resolution crystal structure
of the AcAChBP–4 complex indicated close similarities in the protein–ligand
interactions involving the parts of 4 common to cytisine. The point of difference,
the 3-(hydroxypropyl) substituent, appears to influence the conformation of the
Met133 side chain and helps to form an ordered solvent structure at the edge of
the orthosteric binding site.
1. Introduction
Nicotine (1; Fig. 1) is the archetypical ligand of nicotinic
acetylcholine receptors (nAChRs), a family of excitatory
pentameric ligand-gated ion channels (pLGICs) that contri-
bute to the function of the human peripheral and central
nervous system. This family of receptors is being studied as
they may represent therapeutic targets for Alzheimer’s
disease, Parkinson’s disease and anti-nociception (Quik &
Wonnacott, 2011; Umana et al., 2013; Lombardo & Maskos,
2015). Nicotine is notorious as the agent responsible for the
addictive effects of tobacco smoking, which worldwide is
estimated to have caused six million deaths and 150 million
disability-adjusted life years in 2015, and these numbers are
increasing (GBD 2015 Tobacco Collaborators, 2017).
Cytisine (2; Fig. 1) is a natural product widely distributed in
Cytisus and Laburnum species and is the active component
in the smoking-cessation agent called Tabex, which is used
widely in Central and Eastern Europe. Small-scale trials
comparing cytisine with other smoking-cessation therapies
have suggested that it has an excellent profile in terms of
cessation rate, limited side effects and economical value, and
this has raised interest in the potential use of cytisine in the
wider global market (Hajek et al., 2013; Walker et al., 2014;
ISSN 2053-230X
West et al., 2011). Cytisine, which is structurally related to
nicotine, is a potent agonist at neuronal nAChRs but differs in
displaying only partial agonist activity at 42 nAChRs, the
high-affinity nicotine subtype. It is this combination of high
affinity and partial agonism which has been identified as a
hallmark of clinically successful smoking-cessation agents.
Cytisine, however, also has significant full agonist activity at
the heteromeric 34 and in particular the homomeric 7
nAChRs, which can induce off-target effects (Coe et al., 2005;
Rego Campello et al., 2018). It is of interest therefore to
understand how cytisine and its derivatives might interact with
nAChR subtypes and to use this information to guide modi-
fications that may improve its therapeutic profile. In one such
approach cytisine provided the lead for varenicline (3; Fig. 1),
a smoking-cessation agent marketed as Champix (Coe et al.,
2005). The C(9)-substituted ligand 4 (Fig. 1) is a derivative of
cytisine carrying a 3-(hydroxypropyl) moiety on the pyridone
ring. This offers an additional set of potential interactions
involving the variable complementary -subunit, and it is this
region of the cytisine scaffold that has been associated with
enhanced receptor-subtype discrimination (Rego Campello et
al., 2018). In this study, we sought to compare the binding
parameters and structural interactions of cytisine and ligand 4
using acetylcholine-binding protein (AChBP). AChBP is a
soluble, highly conserved homolog of the nAChR extracellular
domain (ECD) in mollusks such as the Californian sea hare
(Aplysia californica) and can therefore be used as a surrogate
for crystallography and binding studies (see, for example,
Shahsavar et al., 2016; Dawson et al., 2019; Smit et al., 2003).
2. Materials and methods
2.1. Protein production
A recombinant source ofAcAChBP (UniProt ID Q8WSF8)
with a C-terminal Tobacco etch virus cleavage site and His6 tag
was produced in baculovirus-infected Sf9 insect cells using the
Bac-to-Bac system (Thermo Fisher). Suspension High Five
insect cells, cultured in Express Five medium plus 100 U ml1
penicillin/streptomycin and 2 mM l-glutamine (Thermo
Fisher), were used for protein production. 15  105 cells per
millilitre were infected with 5% of the baculovirus and incu-
bated at 27C in shaking flasks for 48 h before being harvested
by centrifugation (1500g for 10 min at 12C followed by 4000g
for 10 min at 12C). The AcAChBP was secreted out to the
medium and, using a Sartojet system with a 10 kDa cutoff
Sartocon Slice filter (Sartorius), the medium was exchanged
for buffer A (50 mM Tris–HCl, 250 mM NaCl pH 7.5) and the
sample was concentrated. The protein solution was applied
onto a 5 ml Ni2+ HisTrap column (GE Life Sciences) equili-
brated in buffer A for immobilized metal-affinity chromato-
graphy. The column was washed with 15 column volumes of
buffer A plus 7.5% buffer B (50 mM Tris–HCl, 250 mM NaCl,
800 mM imidazole pH 7.5) and the product was then eluted
over 30 column volumes using a combination of a stepped and
a linear gradient of buffer B. Fractions were analyzed by stain-
free SDS–PAGE gels (Bio-Rad) and those containing the
desired product were pooled, exchanged into buffer A and
concentrated using 10 kDa centrifugal concentrators (Pall).
Protein destined for use in ITC was dialyzed against buffer A
using SnakeSkin 10 kDa dialysis tubing (Thermo Fisher) prior
to concentration.
2.2. Isothermal titration calorimetry (ITC)
ITC was carried out on a MicroCal PEAQ-ITC instrument
(Malvern Panalytical). Ligands were dissolved in DMSO as
100 mM stocks and the concentration of DMSO was then
matched in the titrant and cell solutions to minimize heat
changes from buffer mismatch. Experiments utilized 12 
3.0 ml or 15  2.5 ml injections, with the reference response of
ligand titrated into buffer being subtracted. All experiments
used a cell temperature of 25C and the data were fitted with a
one-site model using the manufacturer’s software.
2.3. Crystallization
Initial crystallization trials were carried out by mixing 0.1 ml
protein solution with 0.1 ml reservoir solution using MRC
sitting-drop vapor-diffusion plates. A Mosquito crystallization
robot (TPP) was used to prepare the drops, utilizing the
JCSG-plus and Morpheus crystal screens (Molecular Dimen-
sions), with protein solutions of 4 and 10 mg ml1 AcAChBP
incubated with cytisine (3 mM) or ligand 4 (5 mM) for 1 h at
room temperature. The synthesis of 4 will be described else-
where, but is based on the use of enantiomerically pure N-Boc
9-bromocytisine as a substrate for a Pd(0)-mediated cross-
coupling to an alkyl boronate ester (Rouden et al., 2014).
Seeking to increase the number of hits and improve the
quality of the crystals, random matrix microseeding was
implemented as described by Shaw Stewart et al. (2011).
Seeded plates used a protein solution of 12.5 mg ml1 plus
6 mM ligand 4 in 0.6 ml drops (0.3 ml protein solution plus
0.2 ml reservoir plus 0.1 ml seed-stock mixture). Subsequent
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Figure 1
The chemical structures of nicotine {1; 3-[(2S)-1-methyl-2-pyrrolidinyl]-
pyridine}, cytisine [2; {(1R,5S)-1,2,3,4,5,6-hexahydro-1,5-methano-8H-
pyrido[1,2a][1,5]diazocin-8-one}, varenicline {3; (1R,12S)-5,8,14-triaza-
tetracyclo[10.3.1.02,110.04,9]hexadeca-2(11),3,5,7,9-pentaene} and ligand
4 {(1R,5S)-9-(3-hydroxypropyl)-1,2,3,4,5,6-hexahydro-1,5-methano-8H-
pyrido[1,2a][1,5]diazocin-8-one}.
optimization of the identified conditions used 24-well hanging-
drop plates with 2 ml drops (all including 0.3 ml seed stock),
screening the effect of drop ratios, precipitant concentration
and additives (Table 1, Fig. 2a). The crystal used for analysis
grew in a reservoir consisting of 0.8M NaH2PO4, 0.8M
KH2PO4, 10% glycerol, 0.1M HEPES pH 7.0, with the drop
consisting of 1.5 ml protein solution and 0.2 ml reservoir solu-
tion.
2.4. Crystallographic analyses
Crystals were harvested with a nylon loop, cryoprotected
in 20% glycerol made up in the reservoir solution and then
snap-frozen in liquid N2. Diffraction data were recorded on
beamline I03 at Diamond Light Source (DLS; Table 2),
indexed and integrated with DIALS (Winter et al., 2018) and
scaled and merged in AIMLESS (Evans & Murshudov, 2013).
The structure was solved by molecular replacement with
Phaser (McCoy et al., 2007) using the 2.20 A˚ resolution
structure of AcAChBP in complex with an epibatidine deri-
vative as the search model (PDB entry 6qkk; S. Davis, R. V.
Bueno, A. Dawson & W. N. Hunter, unpublished work).
REFMAC v.5.8.0257 (Murshudov et al., 2011) was used for
multiple rounds of automated restrained refinement, with
manual refinement and model building in Coot (Emsley et al.,
2010). MolProbity (Chen et al., 2010) was used for Rama-
chandran analysis. Restraints and models for ligand 4 were
generated using the Grade server (Global Phasing; http://
grade.globalphasing.org/cgi-bin/grade/server.cgi) and graphics
were rendered using the PyMOL molecular-graphics system
(Schro¨dinger). Two pentamers were present in the asymmetric
unit and the ligand 4 was unambiguously placed in every
binding site on the basis of electron and difference density
(see, for example, Fig. 2b). The protein is glycosylated and
N-acetyl-d-glucosamine was modeled onto Asn91 in every
subunit. Strict local noncrystallographic symmetry restraints
were initially applied, but were then relaxed during the course
of refinement. It became evident that multiple conformations
were visible for certain residues and these were manually
assigned, with different occupancies being tested until the
difference density maps suggested appropriate modeling.
During the placement of water molecules it was apparent that
ordered ions and other ligands were also present, and these
were assigned as Cl, K+, glycerol or phosphate. Crystallo-
graphic statistics are given in Table 3.
3. Results and discussion
3.1. Thermodynamic parameters
The ITC measurements for cytisine (2) binding to
AcAChBP (Fig. 3, Table 4) are similar to those previously
research communications
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Table 2
Diffraction data-collection parameters.
Diffraction source Beamline I03, DLS
Wavelength (A˚) 0.976
Temperature (K) 100
Detector EIGER2 XE 16M
Crystal-to-detector distance (mm) 288.18
Rotation range per image () 0.1
Total rotation range () 180
Table 1
Crystallization of the AcAChBP–4 complex.
Method Vapor diffusion
Plate type Hanging drop (Hampton Research)
Temperature (K) 295
Protein concentration (mg ml1) 12.5
Buffer composition of protein
solution
50 mM Tris–HCl, 250 mM NaCl pH 7.5 +
6 mM ligand 4
Composition of reservoir solution 0.8M NaH2PO4, 0.8M KH2PO4,
10% glycerol, 0.1M HEPES pH 7.0
Volume and ratio of drop 1.5 ml protein solution:0.2 ml reservoir
solution:0.3 ml seed stock
Volume of reservoir (ml) 650
Figure 2
(a) Hanging drop containing crystals of the AcAChBP–4 complex. The
largest crystal provided the data used for structure determination. (b) An
OMIT difference density map for ligand 4 contoured at 6.5 standard
deviations (associated with subunit A). C-atom positions of residues on
the principal side of the binding site (subunit A) are shown in brown,
those of residues on the complementary side (subunit D) are in gray and
those for ligand 4 are in black. N and O atoms are colored blue and red,
respectively. Three water molecules are depicted as blue spheres.
Potential hydrogen bonds are identified with blue dashed lines and a
C—H  O interaction is identified with a red dashed line. Two rotamers
for Tyr110 are shown. Distances are in A˚.
published (Rucktooa et al., 2012). For example, the values of
the thermodynamic dissociation constant Kd are 0.6 (0.3)
and 1.6 mM, respectively, and a similar thermodynamic profile
is obtained that indicates that the binding is dominated by a
favorable enthalpic contribution. In the present work H was
measured as 15.2 (1.2) kcal mol1, whilst in the previous
study the value was 13.3 kcal mol1. The small differences
observed are likely to be owing to the use of different buffers
(see, for example, Celie et al., 2004). The affinity of ligand 4 is
significantly reduced compared with that of 2, with Kd values
of 53.3 (19.9) and 0.6 (0.3) mM, respectively. For both 2 and
4 there is an unfavorable entropic contribution of 6.6 (1.4)
and 3.0 (2.8) kcal mol1, respectively, but binding is driven
by gains in enthalpy, as discussed above. For 4, although the
entropic term is less unfavorable, the enthalpic contribution is
reduced and therefore the affinity is lowered. This is consistent
with the general reduction in binding affinity of nAChRs for
cytisine derivatives possessing pyridone-ring modifications
(Rego Campello et al., 2018).
Ligand 4 displays a stoichiometry of approximately 4.5:1 for
interaction with the pentameric AcAChBP (Table 3), which is
close to the expected 5:1 ratio for a ligand that fully occupies
the binding site in a straightforward association. We note,
however, that for 2 the stoichiometry is about 2.8:1. Our data
are strikingly consistent with the previous study of AcAChBP
interacting with 2 (see Fig. 3B in Rucktooa et al., 2012). It has
previously been noted, again using ITC (Celie et al., 2004),
that carbamylcholine binds the pentameric AcAChBP at a
molar ratio of 2.5:1. The agonist carbamylcholine displays a
similar affinity for AcAChBP as 2, 7.6  0.4 mM, and the
reason for the low molar ratio is unclear. The finger of
suspicion would point towards experimental issues such as the
presence of impurities, uncertainty in the concentrations of the
ligand and/or protein, the degradation of reagents or preci-
pitation/aggregation (a particular problem at high concentra-
tions). Alternatively, cooperativity or allosteric transitions can
complicate the analyses. We have not uncovered any proof for
such behavior in AcAChBP in this or previous studies
(Dawson et al., 2019; Jones et al., 2020) and are unable to shed
further light on these observations relating to carbamylcholine
or 2.
3.2. A seeding route for suitable crystals
Attempts to directly co-crystallize ligand 4 with AcAChBP
were unsuccessful. Therefore, AcAChBP was co-crystallized
with 3 mM cytisine for random matrix microseeding. Small
crystals grew in a drop consisting of 5 mg ml1 protein and
0.4M NaH2PO4, 0.4M KH2PO4, 0.05M HEPES pH 7.5.
These crystals were crushed and used to seed drops consisting
of 6.25 mg ml1 AcAChBP plus 3 mM ligand 4 and 3%
DMSO. This generated crystals in the same reservoir condi-
tions as the originating seed stock. Subsequent optimization in
24-well hanging-drop plates led to crystals with maximal
dimensions of400 400 300 mm in 0.8MNaH2PO4, 0.8M
KH2PO4, 10% glycerol, 0.1M HEPES pH 7.0 (Fig. 3). The
drop consisted of 1.5 ml protein solution (12.5 mg ml1
AcAChBP, 6 mM ligand 4, buffer A), 0.2 ml reservoir solution
(0.8MNaH2PO4, 0.8MKH2PO4, 10% glycerol, 0.1MHEPES
pH 7.0) and 0.3 ml seed stock (Fig. 2a). High-quality diffraction
data were measured using synchrotron radiation and the
structure was solved and refined to our satisfaction.
3.3. Structure of the AcAChBP–4 complex
The monoclinic crystal has two pentameric assemblies in
the asymmetric unit. A high degree of noncrystallographic
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Table 3
Crystallographic statistics for the AcAChBP–4 complex.
Values in parentheses are for the highest resolution shell.
Data statistics
Unit-cell parameters (A˚, ) a = 209.5, b = 132.9, c = 131.1,
 = 90.0,  = 102.5,  = 90.0
Space group C2
Wavelength (A˚) 0.976
Subunits per asymmetric unit 10
Resolution range (A˚) 127.97–1.72 (1.75–1.72)
Total No. of reflections 1225936 (25553)
Unique reflections 353432 (12162)
Multiplicity 3.5 (2.1)
Rmerge† 0.07 (0.82)
Rp.i.m. 0.064 (0.794)
Wilson B factor (A˚2) 25.07
Completeness (%) 95.5 (66.6)‡
hI/(I)i 7.6 (0.6)§
CC1/2} 0.993 (0.435)
Refinement
Resolution range (A˚) 90.12–1.72
Rwork/Rfree†† (%) 16.2/19.2
No. of reflections for Rwork/Rfree 335977/17388
No. of protein residues 2058
No. of NAG molecules 10
No. of molecules of 4 10
No. of phosphate molecules 10
No. of glycerol molecules 40
No. of water molecules 2899
No. of chloride ions 10
No. of potassium ions 10
R.m.s.d.s
Bond lengths (A˚) 0.013
Angles () 1.84
Ramachandran plot
Residues in favored regions (%) 98.77
Residues in allowed regions (%) 1.23
Mean B factors (A˚2)
Protein atoms (subunit A–J) 30.1/29.2/29.7/28.4/30.6/29.8/31.5/31.8/
33.4/34.5
NAG molecules (subunit A–J) 93.7/90.2/108.6/87.6/99.5/97.1/104.2/
103.6/100.2/92.6
Water molecules 46.0
Ligand 4 (subunit A–J) 28.1/27.9/23.5/22.2/27.9/29.9/23.7/32.4/
33.3/31.5
Phosphate ions (subunit A–J) 58.1/54.2/57.4/63.8/49.2/49.5/56.4/71.9/
52.6/58.0
Glycerol molecules 59.9
Chloride ions (subunit A–J) 33.7/34.6/32.0/32.9/33.5/34.0/37.9/35.2/
35.9/37.8
Potassium ions (subunit A–J) 37.3/37.4/38.6/40.0/39.5/40.5/41.3/40.5/
43.2/44.2
PDB code 6t9r
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
the ith measurement of reflection hkl and hI(hkl)i is the mean value of Ii(hkl) for all i
measurements. ‡ Completeness was <70% in the highest resolution shell owing to the
use of a square detector for data collection. § hI/(I)i = 2.0 at 1.90 A˚ resolution.
} Pearson correlation coefficient. †† Rwork =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where
Fobs is the observed structure-factor amplitude and Fcalc is the structure-factor amplitude
calculated from the model. Rfree is the same as Rwork except that it was calculated using a
subset (5%) of data that were excluded from refinement calculations.
symmetry is evident even though NCS restraints were released
in the refinement calculations. Electron density for the ligand
is well defined in all ten binding sites and they refined with
average B factors less than or close to the values noted for
their associated subunits (Table 3). The position of the ligand
and interactions formed with the protein are highly conserved
in each binding site and it is only necessary to detail one.
There are two crystal structures with cytisine in the Protein
Data Bank (PDB) that are relevant to our study; a low-
resolution (2.9 A˚) complex with AcAChBP (PDB entry 4bqt;
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Table 4
Thermodynamic parameters.
Values in parentheses indicate the standard errors of the mean.
Ligand
Ligand
concentration (mM)
AcAChBP
concentration (mM)
No. of
sites
Kd
(mM)
G
(kcal mol1)
H
(kcal mol1)
TS
(kcal mol1)
Cytisine (2) (n = 2) 100 20 0.6 (0.01) 0.6 (0.3) 8.6 (0.3) 15.2 (1.2) 6.6 (1.4)
4 (n = 3) 1000 50 0.9 (0.10) 53.3 (19.9) 6.0 (0.3) 9.1 (2.5) 3.0 (2.8)
Figure 3
Raw and injection heat-normalized thermodynamic traces for the binding of (a) cytisine and (b) ligand 4 to AcAChBP and (c, d) the corresponding
signature plots. Error bars represent the standard errors of the mean.
Rucktooa et al., 2012) and a 2.0 A˚ resolution structure (PDB
entry 5syo; J. Bobango, J. Wu, I. T. Talley & T. T. Talley,
unpublished work) in which loop C has been engineered to
incorporate amino acids from the human 3 nAChR. Also of
note is the 2.0 A˚ resolution complex of varencline with
Capitella telata AChBP (PDB entry 4afg; Billen et al., 2012).
The interactions of ligand 4 in the AcAChBP binding site
are similar to those of cytisine (2) and other nAChR ligands,
such as varenicline (3; Fig. 4; Billen et al., 2012; Rucktooa et al.,
2012; Dawson et al., 2019). The Tyr110 OH group and the
carbonyl backbone of Trp164 accept hydrogen bonds from the
secondary amine of the ligand, indicating the presence of a
protonated group. The Tyr110 OH group also donates a
hydrogen bond to the carbonyl group of Ser163. The align-
ment and distances of between 4.6 and 4.2 A˚ of the aromatic
groups on Trp164 and Tyr212, respectively, from the nitrogen
suggest that cation– interactions contribute to binding.
Interestingly, dual rotamers of Tyr110 were modeled in seven
out of ten subunits. The main rotamer, with full occupancy in
three subunits and an occupancy of between 60% and 80% in
the remainder, is that which interacts as described above and
is shown in Fig. 4. In two cases the second rotamer is only
slightly different and still participates in similar interactions.
The rest, in five subunits, adopt a conformer with the OH
group too far away for hydrogen bonding to the ligand. This
rotamer, with occupancies of between 20% and 40%, is that
observed in the apo-form binding site; for example in the three
vacant binding sites of PDB entry 5syo. The orthosteric
binding site of the pLGIC family possesses a degree of plas-
ticity to accommodate ligands of differing properties, and this
is noted in particular for those residues that constitute part of
loop C (see, for example, Dawson et al., 2019). That we also
note the presence of different rotamers for the side chain of
Tyr110 suggests that here also deep in the binding site there
may be a degree of conformational freedom for part of the
aromatic cage.
Tyr205 and Tyr212 participate in van der Waals interactions
with the pyridone ring and with a potential C—H  O inter-
action involving the Tyr212 OH group. The pyridone C O is
about 3.5 A˚ from Trp164 NE1 but the geometry is not optimal
for hydrogen bonding. The ligand carbonyl group accepts a
hydrogen bond, with a distance of 2.7 A˚, donated from a water
molecule that then bridges to Ile135 (via the carbonyl) and
Ile123 (via the amide) on the complementary side of the
binding site. This hydration point is highly conserved in
AcAChBP and nAChR structures, and appears to partially
mediate ligand affinity and possibly the mode of action (Billen
et al., 2012; Zhang et al., 2012). The only available AcAChBP–
cytisine structure (PDB entry 4bqt; Rucktooa et al., 2012) is of
low resolution (2.9 A˚) and does not show any water molecules
in the binding site. However, the higher resolution engineered
AcAChBP–cytisine structure (PDB entry 5syo) with loop C
altered to mimic the human 3 nAChR structure shows a
water molecule in the same position hydrogen-bonded to the
cytisine C O and the complementary side residues as per the
ligand 4 complex structure.
Ligand 4 is primarily hydrophobic, and van der Waals
interactions, which are a major determinant of binding,
between the ring systems and the protein involve Trp164,
Tyr72, Tyr205, Tyr212, Ile135 and Val165, and the disulfide
between Cys207 and Cys208. The 3-hydroxylpropyl substi-
tuent interacts with Val125, Ile135, the Cys207–Cys208 disul-
fide, the side chain of Met133 and the main chain of Phe134.
The hydroxyl residue on 4 is directed out of the binding site,
forming hydrogen bonds to two well ordered water molecules,
which in turn interact with other waters and glycerol. A
glycerol is observed in all ten orthosteric binding sites of the
asymmetric unit and occupies a highly polar pocket created by
the side chains of Asp94, Arg96, Glu170 and Glu210.
The possibility of influencing affinity by virtue of exploiting
waters that are able to form hydrogen-bonding networks to
link the ligand to the protein was a consideration in the design
of 4. However, although the presence of such well ordered
waters may contribute to the formation of a stable complex,
the ITC data indicate that the 3-propylalcohol substituent
leads to a reduced ligand affinity. The program Torsion-
Analyzer (Scha¨rfer et al., 2013) was used to investigate the
conformation of the 3-propylalcohol substituent and to
compare it with structures in the Cambridge Crystallographic
Database. The two torsion angles relevant to the conformation
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Figure 4
Stereoview of ligand 4 in a representative AcAChBP binding site. In this case, the site is formed between subunit A (principal side) and subunit D
(complementary side). A similar color scheme to Fig. 2(b) is used with the following additions: S-atom positions are shown in yellow, glycerol C atoms are
shown in black and the side chain of a Met133 rotamer from a complex with cytisine (PDB entry 5syo) directed into the binding site is shown with blue C
atoms.
of the aliphatic C atoms display values close to60 for all ten
ligands in the asymmetric unit. This matches the well char-
acterized minima expected for a staggered conformation;
moreover, this represents the most prevalent conformation in
the database. This suggests that the ligand has adopted a
preferred low-energy conformation. Nevertheless, the inclu-
sion of the substituent has reduced the affinity for AcAChBP.
An overlay of the complexes with cytisine and 4 identifies
structural perturbation involving Met133. In the cytisine
complexes the side chain of this residue displays a rotamer
that is directed into the binding site and is able to form van der
Waals interactions with the ligand. In the AcAChBP–4
complex we note that the 3-hydroxylpropyl substituent
appears to force the Met133 side chain to adopt different
rotamers and thus avoid steric clash. This may influence the
thermodynamic profile of ligand 4 compared with the cytisine
by virtue of introducing a degree of strain into the protein
structure coupled with a change to the hydration structure
within the binding site. Of note is that in a human 42 nAChR
orthosteric site the residue that corresponds to Met133 in
AcAChBP aligns with Gln150 or Phe144 in the 4 and 2
subtypes, respectively. Modification of the cytisine framework
to enhance activity might have to consider the likelihood of
unfavorable interactions with a sizable and flexible side chain
in this part of the binding site.
4. Conclusions
We have characterized the binding of cytisine and ligand 4,
a novel 9-substitued cytisine variant, to AcAChBP using ITC
and reported the high-resolution crystal structure of the
AcAChBP–4 complex. Ligand 4 carries a 9-(3-hydroxypropyl)
modification and this reduces its affinity for AcAChBP.
Structural comparisons indicate that the molecular interactions
involving the identical components of cytisine and ligand 4 are
conserved. There is only a minor perturbation of the protein
structure at the side chain of Met133, where a steric clash is
likely to contribute to the reduced affinity of 4 compared with
the parent compound. The complex structure suggests that
recovery of affinity may be possible with substituents that
interact with a polar patch at the periphery of the binding site.
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